Exact Mass: 347.1553
Exact Mass Matches: 347.1553
Found 87 metabolites which its exact mass value is equals to given mass value 347.1553,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D002120 - Calcium Channel Agonists D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
AS 1842856
5-Amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide
3-(4-((3-Phenoxybenzyl)amino)phenyl)propanoic acid
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
10,20-Dehydro[12,13-dehydroprolyl]-2-(1,1-dimethylallyltryptophyl)diketopiperazine
GW9508
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
GW 9508
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities[1][2][3][4].
[5-(4-Methylphenyl)-1,2-oxazol-4-yl](4-phenyl-1-piperazinyl)metha none
Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N-phenyl- (9CI)
(E)-Methyl 3-(2-((tert-butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-yl)acrylate
Adiphenine Hydrochloride
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects[1][2][3].
(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride
(3R)-3-Piperidinecarboxylic acid, 3-(phenylmethyl)-, 1,2,2-trimethylhydrazide, hydrochloride (1:2)
6-nitro-2-[(4-phenylpiperidin-1-yl)methyl]quinoline
N-cyclopropyl-2,6-dimethyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
N-(Cyclopropylmethyl)-2-Methyl-5-(5-Methyl-1,3,4-Oxadiazol-2-Yl)biphenyl-4-Carboxamide
(1E,2Z)-3-hydroxy-5,9,17-trioxo-4,5:9,10-disecoandrosta-1(10),2-dien-4-oate
(1R,2R,5R,8R,9S,10R,11R,12R,13S)-12,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(1R,2R,5S,8S,9S,10R,11R,12S)-5,12-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
(1R,2R,5S,8S,9S,10R,11S,13R)-5,13-dihydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylate
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine
2-hydroxy-2,2-bis(4-methylphenyl)-N-(2-pyridinyl)acetohydrazide
1-[2-(Dimethylamino)ethyl]-3-(2,4-dimethylphenyl)-1-(thiophen-2-ylmethyl)thiourea
3-(1,3-Dihydrobenzimidazol-2-ylidene)-1-pentylquinoline-2,4-dione
7-(diethylamino)-4-(1-methyl-1H-benzimidazol-2-yl)-2H-chromen-2-one
5-dioxooctahydro-1H-inden-4-yl]-6-oxoocta-2,4-dienoate
(2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
Butyl N-trifluoroacetyl 2-N-methylaminoethyl phosphonate
Dibutyl 1-(N-trifuoroacetylamino)propylphosphonate
GP531
GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
